- Home
- THM vs SLS Comparison
THM vs SLS Comparison
Compare THM & SLS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | THM | SLS |
|---|---|---|
| Founded | 1978 | 2012 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 723.2M | 706.7M |
| IPO Year | 2002 | 2007 |
Fundamental Metrics
Financial Performance| Metric | THM | SLS |
|---|---|---|
| Price | $2.57 | $5.27 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $7.00 |
| AVG Volume (30 Days) | 1.6M | ★ 5.9M |
| Earning Date | 01-01-0001 | 04-16-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 62.69 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | $0.46 | $0.95 |
| 52 Week High | $3.65 | $6.14 |
Technical Indicators
Market Signals| Indicator | THM | SLS |
|---|---|---|
| Relative Strength Index (RSI) | 41.87 | 57.53 |
| Support Level | $2.17 | $1.48 |
| Resistance Level | $3.63 | N/A |
| Average True Range (ATR) | 0.28 | 0.53 |
| MACD | -0.08 | 0.00 |
| Stochastic Oscillator | 3.13 | 51.69 |
Price Performance
Historical ComparisonAbout THM International Tower Hill Mines Ltd. (Canada)
International Tower Hill Mines Ltd is a mining company. It is engaged in the acquisition, exploration, and development of mineral properties. The company holds interests in an exploration project namely the Livengood Gold Project. It is located in northwest of Fairbanks, Alaska in the Tolovana mining district within the Tintina gold belt. The project property consists of land leased from the Alaska Mental Health Trust, several smaller private mineral leases, Alaska state mining claims purchased or located by the company, and the patented ground held by the company.
About SLS SELLAS Life Sciences Group Inc.
SELLAS Life Sciences Group Inc is a late-stage clinical biopharmaceutical company focused on the development of novel therapeutics for a broad range of cancer indications. The company's product candidates currently include galinpepimut-S, or GPS, a peptide immunotherapy directed against the Wilms tumor 1, or WT1, antigen, and GFH009, a selective small molecule cyclin-dependent kinase 9, or CDK9, inhibitor.